COSCIENS Financial Statements From 2010 to 2024

CSCI Stock   2.92  0.21  6.71%   
COSCIENS Biopharma financial statements provide useful quarterly and yearly information to potential COSCIENS Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on COSCIENS Biopharma financial statements helps investors assess COSCIENS Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting COSCIENS Biopharma's valuation are summarized below:
Market Capitalization
13.1 M
Enterprise Value Revenue
2.6735
Revenue
4.9 M
Earnings Share
(2.69)
Quarterly Revenue Growth
0.041
We have found fourty-eight available fundamental signals for COSCIENS Biopharma, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of COSCIENS Biopharma prevailing fundamentals against the fundamentals between 2010 and 2024 to make sure the company is sustainable this year.

COSCIENS Biopharma Total Revenue

9.3 Million

Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 200.3 K, Interest Expense of 89.8 K or Selling General Administrative of 3.7 M, as well as many indicators such as . COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
  
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.

COSCIENS Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Long Term Debt37.7 K42.4 K46.2 K
Slightly volatile
Short and Long Term Debt85.5 K65 K118.8 K
Slightly volatile
Total Assets35.6 M31.4 M30.5 M
Slightly volatile
Total Current Liabilities1.7 M1.7 M1.5 M
Slightly volatile
Total Stockholder Equity30.8 M27.9 M25.7 M
Slightly volatile
Property Plant And Equipment Net13.5 M15.4 M17.8 M
Slightly volatile
Retained Earnings7.3 M6.2 M4.3 M
Slightly volatile
Cash9.8 M8.8 M6.6 M
Slightly volatile
Non Current Assets Total14.5 M16.6 M19.3 M
Slightly volatile
Net Receivables119.8 K126.1 K1.4 M
Slightly volatile
Common Stock Shares Outstanding85.8 M78.3 M78.3 M
Slightly volatile
Non Current Liabilities Total2.2 M1.9 M3.2 M
Slightly volatile
Capital Lease Obligations2.1 M2.2 M2.8 M
Slightly volatile
Inventory3.5 M5.3 M1.9 M
Slightly volatile
Total Liabilities3.5 M3.6 M4.7 M
Slightly volatile
Net Invested Capital30.9 M27.9 M25.8 M
Slightly volatile
Property Plant And Equipment Gross30.2 M28.4 M27 M
Slightly volatile
Total Current Assets15.6 M14.8 M10.9 M
Slightly volatile
Capital Stock18.3 M16.7 M16.7 M
Slightly volatile
Net Working Capital13.9 M13.1 M9.4 M
Slightly volatile
Intangible Assets11.3 K9.6 K16.8 K
Slightly volatile
Non Currrent Assets OtherKK9.8 K
Slightly volatile

COSCIENS Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense89.8 K96.6 K127.5 K
Slightly volatile
Selling General Administrative3.7 M5.6 M2.9 M
Slightly volatile
Total Revenue9.3 M7.3 M11.6 M
Slightly volatile
Gross Profit5.1 MMM
Very volatile
Research Development2.2 M2.1 M1.7 M
Slightly volatile
Cost Of Revenue4.2 M4.3 M5.6 M
Slightly volatile
Total Operating Expenses11.7 M12 M10.3 M
Slightly volatile
Reconciled Depreciation1.6 M1.5 M1.5 M
Slightly volatile
Interest Income218.6 K328.8 K96 K
Slightly volatile

COSCIENS Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation120.9 K195.2 K128.6 K
Pretty Stable
Begin Period Cash FlowM10.4 M3.4 M
Slightly volatile
Depreciation1.4 M1.5 M1.8 M
Slightly volatile
Other Non Cash Items110.9 K96.6 K161.9 K
Slightly volatile
Capital Expenditures675.4 K739.3 K621.5 K
Very volatile
End Period Cash Flow9.2 M6.7 M6.4 M
Slightly volatile

About COSCIENS Biopharma Financial Statements

Investors use fundamental indicators, such as COSCIENS Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Revenue7.3 M9.3 M
Cost Of Revenue4.3 M4.2 M

Currently Active Assets on Macroaxis

When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.69)
Revenue Per Share
3.759
Quarterly Revenue Growth
0.041
Return On Assets
(0.23)
Return On Equity
(0.66)
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.